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In drug therapy, most therapeutic drugs are of low molecular weight and could freely diffuse in the 
biological milieu depending on the administration route applied. The main reason for the development of 
polymeric drug carriers is to obtain desired effects such as sustained therapy, local and controlled 
release, prolonged activity and reduction of side effects. Alternatively, polymeric carriers can be made 
bioerodible in order to be eliminated by natural ways after a certain time of therapy. Core-shell fibres from 
coaxial spinneret or emulsion electrospinning are good candidates for the development of such devices; 
however difficulties remain especially in controlling the release over a sustained period. Here, we present 
a novel technique combining coaxial and emulsion electrospinning to produce micro-structured core-shell 
fibres. The design of drug microreservoirs of variable size within the bulk of the fibre combined with a 
tailored diffusive barrier allows modulating the release kinetics of these novel carriers. A nearly constant 
and linear release of the model drug Levetiracetam (M w ≈ 170 g mol -1) from PLGA emulsion-coaxial 
electrospun fibres is observed over 20 days. This device is aimed to be implanted into the brain for the 
treatment of epilepsy and is an example of the new capabilities and the promising potential that 
emulsion-coaxial electrospinning can provide towards the development of future drug carriers. 
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In drug therapy, most therapeutic drugs are of low molecular weight and could freely diffuse in the
biological milieu depending on the administration route applied. The main reason for the development
of polymeric drug carriers is to obtain desired effects such as sustained therapy, local and controlled
release, prolonged activity and reduction of side effects. Alternatively, polymeric carriers can be made
bioerodible in order to be eliminated by natural ways after a certain time of therapy. Core–shell fibres
from coaxial spinneret or emulsion electrospinning are good candidates for the development of such
devices; however difficulties remain especially in controlling the release over a sustained period. Here,
we present a novel technique combining coaxial and emulsion electrospinning to produce micro-
structured core–shell fibres. The design of drug microreservoirs of variable size within the bulk of the
fibre combined with a tailored diffusive barrier allows modulating the release kinetics of these novel
carriers. A nearly constant and linear release of the model drug Levetiracetam (Mw z 170 g mol
1)
from PLGA emulsion-coaxial electrospun fibres is observed over 20 days. This device is aimed to be
implanted into the brain for the treatment of epilepsy and is an example of the new capabilities and the
promising potential that emulsion-coaxial electrospinning can provide towards the development of
future drug carriers.
Introduction
Among several methods for preparing bioactive loaded polymer
structures for drug delivery, the electrospinning technique pres-
ents a number of advantages, in particular, the possibility to
fabricate high specific surface area structures in a facile approach
requiring mild preparation.1 Electrospun fibres have been
successfully developed for the encapsulation and the delivery of
bioactive compounds within the body for therapeutic treat-
ments.2–20 Whatever the route of delivery, the polymeric device is
usually required to release the drug with zero-order kinetics.21 In
the quest to produce a delivery device which has appropriate
kinetics, a number of strategies have been developed including
controlled erosion of the surface of the polymeric carrier loaded
with a drug.4,10,22,23 In these devices the rate of erosion has to be
faster than the rate of drug diffusion, and the penetration of
a solvent front into the polymer should be constant.15,24–26 Zero
order kinetics implies a homogeneous drug distribution and
a release profile governed by the wetting properties of the
material. Nevertheless, some issues remain, especially concerning
the encapsulation of highly hydrophilic and neutrally charged
drugs of low molecular weight.12,27–29 The interaction of these
types of molecules with the polymer is usually very poor and their
rate of diffusion is often faster than the rate of polymer erosion.
This fast rate of diffusion has detrimental effects on drug release
from electrospun polymer structures. Typically drug enrichment
at the surface of electrospun fibres occurs when the drug is
blended into a polymer solution prior to electrospinning, and
results in a severe burst release phenomenon.30 This burst release
reduces the effective lifetime of the delivery device.
Finding ways to regulate encapsulation efficiency and thus
release profiles would greatly add to the inventory of strategies
available for designing sustained delivery systems. A simple
approach is to create a membrane-reservoir device in which an
excess of the drug is surrounded by a rate-controlling membrane.
Significant interest towards the fabrication of core–shell fibrous
structures for biomedical applications has led to the development
of coaxial electrospinning.3,31 A coaxial dual-capillary spinneret,
whereby a capillary is surrounded by a larger one (Fig. 1A), has
been employed in electrospinning to fabricate core–sheath
structures providing a more effective method of encapsulation
for bioactive additives and hence providing a suitable drug
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distribution in the polymeric fibres.2,14 The polymer shell
provides a diffuse barrier minimizing the surface enrichment. At
the same time, water-soluble bioactive agents in droplets could
be electrospun within hydrophobic polymers by electrospinning
of water-in-oil (W/O) emulsions, namely emulsion electro-
spinning.32–36 Emulsion electrospinning is similar to normal
solution electrospinning, except that the solution is replaced by
an emulsion. During electrospinning, the aqueous drops are
stretched into elliptical shapes in the axial direction of fibres and
give rise to a continuous core. The organic solvent evaporates
faster than the water phase and its viscosity increases more
rapidly leading to solidification and the formation of a core–shell
structure.
With the continual development of new pharmaceutical drugs
the delivery technologies have to face many physical–chemical
issues concerning the design of suitable carriers. And when
considering low molecular weight molecules presenting a high
affinity for many solvents, emulsion or coaxial electrospinning
may not be versatile enough to assure a reasonable encapsulation
of the drug inside a local delivery system.
In this paper we present a protocol that enables drug encap-
sulation in order to modulate the release of a low molecular
weight (170.2 g mol1) antiepileptic drug, Levetiracetam (Lev)
from a microfibre structure. We employed coaxial electro-
spinning using an emulsion in the core as a novel way to facilitate
microstructuring of fibres and the formation of drug reservoirs.
The combination of the emulsion electrospinning with the
coaxial electrospinning techniques provides a solution to inte-
grate a low molecular weight, highly soluble drug into microfibre
mats. Droplets containing Lev are emulsified in a drug-free
polymer solution which is then coaxially electrospun with
another polymer solution free of drug. Microstructured-core
fibres are obtained from emulsion/coaxial electrospinning while
solid-core microfiber structures resulted from coaxial electro-
spinning technique. The design of drug micro-reservoirs of
variable size within the bulk of the fibre combined with a tailored




Poly(D,L-lactic-co-glycolic acid) (PLGA) (Mw z 60 000 Da) with
varying molar co-ratios was purchased from Purac (Singapore)
and used as received. 75 : 25 PLGA identifies the copolymer
whose composition is 75% lactic acid and 25% glycolic acid, and
85 : 15 PLGA identifies the copolymer whose composition is 85%
lactic acid and 15% glycolic acid. Dichloromethane (DCM) and
dimethylformamide (DMF) of analytical grade were obtained
from ChemSupply PTY Ltd. Acetonitrile (ACN) of HPLC grade
was purchased from Honeywell. Artificial cerebrospinal fluid
(aCSF, pH 6.8) was prepared by mixing the appropriate amount
of salts in Milli-Q water (18 MU cm1) and used as medium for
the in vitro study. The antiepileptic drug Levetiracetam (Lev) was
a gift from UCB Pharma (USA). The solubility of Lev in water is
1.04 g mL1 and in DCM is 0.22 g mL1.
Reverse emulsion for electrospinning
A 17% (w/v) Lev solution in water (Milli-Q) was emulsified by
vortexing in a 14% (w/v) PLGA (75 : 25) solution prepared in
DCM. The aqueous phase containing Lev is the dispersed phase
whereas the PLGA solution (oil phase) constitutes the contin-
uous phase. Different dispersed-to-continuous phase volume
ratios (1/55 and 1/5) were used. The reverse emulsion was sta-
bilised with Tween 20 (0.25% w/v) and used as a core solution for
electrospinning.
Fabrication of emulsion/coaxial electrospun fibres
The coaxial electrospinning set-up used in this study involved
a tailor-made spinneret schematically shown in Fig. 1. The outer
fluid (sheath) was a solution of 85 : 15 or 75 : 25 PLGA (20%w/v)
in DCM : DMF (70 : 30). A reverse emulsion in which the drug is
dissolved in water and emulsified in the polymer solution as
described above was electrospun coaxially as the core. The feed
rates were 2.0 mL h1 and 1.0 mL h1 for the core and sheath
solution, respectively. Fibres were collected on a rotating disc
collector. The needle tip–collector distance was maintained at
15 cm, and the spinning voltage was 24 kV. These fibres will be
referred to as ‘‘emulsion/coaxial’’ fibres.
Fig. 1 Schematic drawing of the electrospinning setup (A) in the coaxial
(B) and coaxial/emulsion (C) configuration showing schematics of the
corresponding fibre structures produced from each method.


































































Fabrication of coaxial electrospun fibres
To compare with the drug blended in the core solution instead of
being emulsified in an aqueous dispersed phase, 10 mg of Lev was
dissolved in a 14% (w/v) 75 : 25 PLGA solution prepared in
DCM constituting the inner solution. The outer fluid (sheath)
was a solution of 85 : 15 PLGA or 75 : 25 PLGA (20% w/v) in
DCM : DMF (70 : 30). Fibres were electrospun keeping the
same conditions described previously. These fibres will be
referred to as ‘‘coaxial’’ fibres.
In the case of the emulsion/coaxial electrospinning technique
the drug is no longer blended in a polymer solution rather than
dispersed in the aqueous phase which is then emulsified in
a polymer solution to be used as a core.
Morphology
Morphological analysis was performed using a scanning electron
microscope (SEM) (Jeol SEM) and an optical microscope (Leica
DMEP). Samples at different times of incubation (t ¼ 0, 1, 5 and
20 days) were visualized in order to collect information con-
cerning the degradation of fibres. Cryo-fracturing was performed
in liquid nitrogen in order to visualize the cross-section of the
fibres. SEM samples were sputter-coated with a thin layer of
platinum to eliminate sample charging. The diameters of the
fibres were estimated from SEM images. Average pore diameters
were determined by measuring the pore size for each emulsion
ratio, namely 1/5 and 1/55, in the appropriate SEM images.
Swelling behaviour and contact angle
The swelling behaviour and mass loss were evaluated by incu-
bating electrospun fibres of known weight (wi) and geometrical
surface area (ai) in aCSF (pH 6.8) in a shaking bath at 37
C. At
different time points, samples were removed from the incubation
milieu, blotted carefully with a paper and the wet surface area
(aw) was measured. The geometrical surface area of each sample
was deducted from median width and length measured with
a ruler. Samples were then dried for two days under vacuum and
their dry weights (wd) measured. The percentage size swelling
ratio (Sa) and mass loss were calculated as follows:
%Sa ¼ ðaw  aiÞ
ai
 100
% mass loss ¼ ðwd  wiÞ
wi
 100
All experiments were performed in duplicate and the values
averaged.
Contact angle measurements were obtained using a Data
physics contact angle goniometer (contact angle system OCA).
The data were obtained by averaging at least seven separate
measurements.
Drug loading and in vitro release study
Experimental loading efficiency of Lev per unit weight of fibres
was measured by a previously published extraction method.37 A
certain amount of material was dissolved in DCM (1 mL). Milli-
Q water (10 mL) was added, vortexed for 2 minutes and left for
clarification overnight. Samples from the water phase were
collected and Lev concentration was quantified by high-perfor-
mance liquid chromatography (HPLC, Shimadzu). Lev was
detected at 205 nm (Shimadzu SPD 20A UV-Vis detector). The
mobile phase, ACN (7% v/v) in purified water, was used at a flow
rate of 1.2 mL min1 in an Atlantis T3 reversed-phase C18
column. The injected volume of each sample was 10 mL and the
retention time was 11 min. Prior to each measure, a calibration
curve was prepared using 5, 10, 20 and 40 mL mL1 Lev in aCSF
calibrants and a correlation factor of 0.99 was obtained. The
amount of Lev (Mtot) present in the sample was deducted from
the calibration curve.
Drug release studies were performed on the fabricated samples
in aCSF at 37 C. Fibres of knownmass and dimension (typically
1 cm  1 cm) were incubated in triplicate into 1 mL of artificial
cerebrospinal fluid (aCSF, pH 6.8) in a shaking bath at 37 C.
The release of Lev was followed over about a period of one
month. At appropriate time intervals, all of the aCSF solution
was removed from the incubated samples and replaced with an
equal volume of fresh aCSF solution. The amount of Lev
released (Mt) was determined by analysing the collected solutions
by HPLC (Shimadzu, Prominence) following the procedure
described above. All cumulative release data are plotted as an
amount (Mt) released relative to the Lev loading (Mtot).
Results
As illustrated in Fig. 2, Lev presents a solubility range which
covers a large portion of common solvents, therefore presenting
difficulties in ensuring encapsulation. In order to successfully
encapsulate Lev and obtain suitable long term delivery we
employed a coaxial electrospinning using an emulsion in the core
as a novel way to facilitate microstructuring of the core of
microfibres and the formation of drug reservoirs. Here, we
Fig. 2 The chemical structure of Levetiracetam and Teas graph repre-
sentation of the solubility parameters for common PLGA solvents (1:
tetrahydrofuran, 2: dichloromethane, 3: chloroform, 4: dimethylforma-
mide, 5: ethylacetate, 6: acetonitrile, and 7: acetone). Additionally, water
and ethanol are represented on the graph by an asterisk; they are PLGA
non-solvent. The shaded area represents the solubility range of Lev.


































































present the advantage of such a combination in the design of
specific drug carrier structures.
Morphology of coaxial and emulsion/coaxial fibres
The wetting behaviour of electrospun fibres with different PLGA
co-ratios constituting the sheath was determined by contact
angle measurements of aCSF on the surface of the electrospun
structures. Both the 75 : 25 and 85 : 15 PLGA sheath fibres
exhibit hydrophobic properties with contact angles of 132.6 and
145.1 respectively. In order to slow down the rate of aCSF
uptake by the fibres the more hydrophobic 85 : 15 PLGA was
chosen as the shell polymer whilst the 75 : 25 was chosen as the
core. Furthermore, glycolic acid rich PLGA has higher affinity
with Lev due to the hydrophilic–hydrophilic interaction. The
enhanced affinity could prevent the drug from diffusing into the
shell and thus increasing the encapsulation efficiency and loading
capacity during the fabrication.
From Fig. 3A and B, it can be observed that the external
morphology of emulsion/coaxial and coaxial fibres is the same.
Bead-free fibres with an average diameter of 1.0  0.5 mm were
obtained. However, the internal structure varied between the two
types of fibres. The cross-section of electrospun coaxial fibres
presented a continuous core (Fig. 3C), whereas the use of an
emulsion as core feeding (as described previously) allowed the
formation of a unique microstructure comprising microcavities
within the fibre bulk (Fig. 3D). During electrospinning, the fast
evaporation of DCM allows a rapid precipitation of the polymer
around individual water droplets present in the emulsion,
resulting in the formation of cavities within the core. After the
polymer hardens and the water evaporates, the core architecture
fragments into several drug containing reservoirs. The size of the
cavities is governed by the stability of the emulsion and the
number of cavities is controlled via the dispersed-to-continuous
phase volume ratio of the emulsion. Analysis of the SEMs
obtained for the 1/5 and 1/55 ratio samples showed an average
pore size of 0.91  0.09 mm (n ¼ 59) and 0.72  0.06 mm (n ¼ 61)
respectively.
The introduction of an emulsified core in the coaxial electro-
spinning technique leads to an extremely versatile design process
for structuring the core of the fibres. Fig. 3E and F show emul-
sion/coaxial fibres resulting from 1/5 and 1/55 dispersed-to-
continuous phase volume ratio respectively. It was observed that
using a larger phase ratio of 1/5, numerous cavities were formed
and the cavity wall thickness was thin (solid arrow for cavity and
dashed arrow for wall in Fig. 3E), whereas a smaller phase ratio
led to the formation of fewer small cavities separated by thick
walls (solid arrow for cavity and dashed arrow for wall in
Fig. 3F). Using a large dispersed-to-continuous phase volume
ratio which involves a large aqueous phase volume leads to
a large number of droplets emulsified within the polymer
continuous phase, therefore, allowing the formation of
numerous cavities in the core separated by thin walls. On the
other hand, using a small ratio involves a small aqueous phase
volume forming fewer cavities separated by thick walls after
hardening. In this study, a very small phase ratio of 1/55 was
chosen mainly for two reasons: first to obtain few small cavities
within the core acting like small reservoirs of the drug and
secondly to build thicker cavity walls in order to provide a longer
distance for the drug to diffuse from the cavity reservoir to the
released environment through the membrane formed by the
polymeric matrix of the core and the shell of each fibre (Fig. 4).
Under physiological conditions (incubation in aCSF, pH 6.8
at 37 C), both types of electrospun fibres showed considerable
shrinkage of 70% of the initial area after 1 day of incubation
(Fig. 5A and B). This phenomenon has been previously repor-
ted.8,38–41 After one day of incubation, it is expected that a drastic
shrinkage of the amorphous poly(D,L-lactide-co-glycolide) fibres
takes place. This occurs for the following reasons: (i) PLGA
fibres have a glass transition between 44 C and 48 C (data not
shown) close to the incubation temperature (37 C) and (ii) both
electrospun PLGA fibres are highly oriented (due to the elec-
trospinning process) but without crystalline properties. As
a result, the relaxation of extended amorphous chains under
incubation conditions near the glass transition temperature
causes a large dimensional change (shrinkage) without being
hindered by crystalline regions.
Fig. 5C and D show SEM images recorded at different time
points. No hydrolysis induced porosity or cracks induced by
degradation were observed with fibres keeping a relatively
Fig. 3 Electrospun fibres consisting of PLGA 75 : 25 core and 85 : 15
sheath observed by SEM: top view (A and B) and cross-section (C, D, E
and F). Coaxial fibre cores (A and C) were formed from a PLGA solution
in which Lev was blended and emulsion/coaxial fibre cores (B, D, E and
F) were formed from a reverse emulsion in which Lev was dispersed in the
aqueous phase. The dispersed-to-continuous phase volume ratio is used
to control the cavity size and diffusive length of the release system. A
small ratio (1/55) (F) allows the formation of small cavities (line arrow)
and a large diffusive membrane (dash arrow), whereas a bigger ratio (1/5)
(E) allows larger cavities (line arrow) and shorter diffusive length (dash
arrow). Scale bars are 1 mm.


































































smooth surface over a 20 day time period. No significant mass
loss was observed up to 20 days of incubation. Beyond 20 days,
2% and 9% mass loss were recorded for the coaxial or the
emulsion/coaxial fibres, respectively. These observations suggest
that PLGA electrospun fibre degradation is most likely to occur
from the internal part (bulk) and this is in accordance with
previous observations.13 We believe that the mass loss difference
between coaxial and emulsion/coaxial fibres is due to the erosion
rate taking place within the different structured cores. Since the
emulsion/coaxial fibre core presents a higher internal surface
area, due to the presence of cavities, the erosion front formed
along each cavity wall is larger. Thus, a larger amount of material
eroded from the emulsion/coaxial fibres than from the coaxial
fibres is expected to be observed.
Drug release
The in vitro release profiles of the coaxial and emulsion/coaxial
fibres are shown in Fig. 6. The total Lev loading of the samples
was experimentally calculated to be 2.8  0.3 mg mg1 for both
type of microfibres. Release profiles show a variation between the
coaxial and emulsion/coaxial electrospun carriers for the same
drug loading. A nearly linear sustained release is obtained over
18 days for emulsion/coaxial fibres. The rate of release over time
is nearly constant with some little variation and was evaluated at
about 1% of the total loading amount released per day, whereas
from coaxial fibres a decline in the rate of release over 4 days was
observed. After 18 days, 47% of the total drug loading amount
has been released from emulsion/coaxial fibres whereas from
coaxial fibres the same amount has been released in less than 4
days. Halliday et al.42 recently reported release of Lev from
PLGA sheets and wet-spun fibres. Their results showed that
PLGA flat sheets containing Lev produced a burst release of 56%
of the loaded drug in the first 24 hours followed by 90% release
by day 7. The wet-spun fibres also show significant burst release
of 69% in 24 hours followed by 80% by day 7. The release profiles
presented in Fig. 6 clearly show improved encapsulation and
release from the coaxial and emulsion/coaxial electrospun fibres
compared to these sheets and wet-spun fibres.
Discussion
During the first 20 days of incubation, no significant mass loss
was observed from the electrospun fibres, however Lev release
does occur. This suggests that the diffusion of the drug through
the polymeric matrix is faster than the matrix erosion kinetics.
Hence, within the time frame for this study, we considered that
the release of Lev from the fibres is mainly governed by diffusion
processes. The concentration gradient is the driving force for
diffusion (First Fick’s law) and, in such systems the driving
concentration gradient is between the drug reservoir and the
Fig. 4 Cross-section schematic representation of the diffusive length
with coaxial (A) and emulsion/coaxial (B) fibre architectures.
Fig. 5 Emulsion/coaxial fibres before (A and C) and after (B and D) 20
days of incubation in aCSF, pH 6.8, at 37 C. Scale bars are 1 mm.
Fig. 6 Cumulative release of Lev in aCSF (37 C, pH 6.8) from coaxial
(,) and emulsion/coaxial (>) electrospun fibres. Drug amount (Mt)
released relative to drug loading (Mtot) of the carrier. Error bars represent
standard errors from the average calculated on three specimens.


































































release environment. In our system Lev is located within cavities
in the core of the fibres and partitioned from the release envi-
ronment by the polymeric matrix which constitutes a rate
controlling membrane. Lev will diffuse across the membrane to
finally move into the release environment. Therefore drug
distribution within a device is of primary importance in the
design of a drug carrier. A near constant rate of release can be
achieved if the drug reservoir remains saturated with drug and
the rate of transport across the membrane is sufficiently low
compared to the rate of substance clearance into the release
environment.
In our study we can observe, in the first 3 hours, a relatively
low burst release of drug of about 10% of the loading for both
types of fibres (coaxial and emulsion/coaxial). This burst is likely
due to the presence of small amounts of Lev in the shell of the
fibres that diffuse from the loaded core during the fabrication
process. In addition, since no prewashing of the fibres was per-
formed prior to undertaking the release experiments this burst
release could also be attributed to any surface bound drug.
Following this fast release of drug, a concentration gradient is
established within the device, between the drug reservoir and the
release environment, and is reflected in the release profile
obtained from the fibres. The release profile from the coaxial
fibres presents a linear profile up to 4 days which is followed by
a progressive slowdown of the release, whereas release from
emulsion/coaxial fibres presents a slower and nearly constant
release over 20 days. This differentiation in the release behaviour
between these two types of fibres is believed to be induced by the
microstructuring of the core and the Lev confinement within the
core of the emulsion/coaxial fibres. In the case of coaxial fibres,
the diffuse distance, between the polymeric matrix forming the
core of fibres and the release environment, is smaller than for
the emulsion/coaxial fibres. The diffuse length consists of the
continuous polymeric matrix in the core and the shell thickness
(see Fig. 4A and B). Moreover, the drug reservoir for coaxial
fibres constitutes the whole core of the fibre where the drug is
dispersed homogeneously, whereas emulsion/coaxial fibres
provide small fragmented reservoirs located in the core. As
a result, we observe in the coaxial fibre release profile a short
linear part up to 4 days reflecting the concentration gradient of
the drug established within the small diffusive membrane. At
times longer than 8 days the rate of release appears to slow down,
possibly due to a reservoir which is no longer saturated with
drug. Emulsion/coaxial fibres provide a long diffuse distance and
a saturated reservoir which allow the establishment of a low
concentration gradient slowing down the release of drug up to at
least 18 days of incubation following the formulation used in this
study. A better confinement of the drug inside the cavity-like core
and a large diffusive barrier are efficient enough to provide
a sustained release of highly soluble low molecular weight drug
for many days.
Conclusions
In summary, we have developed an extremely versatile and
powerful electrospinning technique to fabricate novel drug
delivery platforms. We successfully showed that by using reverse
emulsion as a core feed new fibre architectures can be designed.
This technique provides a microstructured core which can be
used as small drug reservoirs surrounded by a diffusive barrier
producing new dimensions in the design of polymeric drug
carriers. A nearly linear release of small molecular weight drug
over 18 days was observed whereas classical core–shell fibres in
comparison provided a linear release for 4 days followed by
a steady state. The internal fibre architecture can be tailored by
adjusting the emulsion dispersed-to-continuous phase ratio.
Finally, emulsion-coaxial electrospinning represents a new and
promising approach for the design of future drug carriers.
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